Demonstrates efficient synthesis of selenium-nitrogen heterocycles, suggesting new pathways for drug development.
Cycloaddition reactions are central to building cyclic molecular architectures for drug discovery and materials science. However, controlling single-atom-bridged cycloaddition remains elusive. Herein, we describe a selenium-atom transfer [3 + 2 + 1] heterocycloaddition of readily available arylamines, alkenes and diselenides, enabling rapid, modular access to diverse selenium- and nitrogen-containing heterocycles, including selenomorpholines and polycyclic 1,4-selenazinanes. This metal-free method operates under mild, simple conditions with scalability, showcasing broad substrate generality and functional group tolerance, is amenable to scalable synthesis, and demonstrates utility in the late-stage skeletal diversification of complex molecules. Mechanistic and computational studies reveal a Se-bridged cycloaddition pathway involving alkene aminoselenylation, followed by electrophilic selenocyclization and deprotonative rearomatization. This heteroatom-driven annulation opens opportunities for the development of reactions for the construction of multi-heteroatom cyclic scaffolds and broader application in selenium-based medicinal chemistry. Cycloaddition reactions enable rapid assembly of cyclic molecular frameworks, yet precise control of single-atom bridged variants remains challenging. Here, the authors report a metal-free selenium-atom transfer [3+2+1] heterocycloaddition that efficiently constructs diverse selenium–nitrogen heterocycles.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: